Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $177.00 Consensus PT from Brokerages

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have been assigned an average recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $177.00.

A number of research analysts recently weighed in on the stock. Piper Sandler reissued an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Needham & Company LLC restated a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Finally, TD Cowen lowered their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th.

Jazz Pharmaceuticals Trading Up 0.6 %

Shares of Jazz Pharmaceuticals stock opened at $125.05 on Tuesday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a fifty day simple moving average of $122.74 and a 200 day simple moving average of $115.83. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $134.17. The company has a market capitalization of $7.56 billion, a P/E ratio of 17.61, a price-to-earnings-growth ratio of 0.87 and a beta of 0.56.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,253 shares of company stock worth $890,594. 4.20% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. CWA Asset Management Group LLC purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at about $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Centre Asset Management LLC purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $9,335,000. Pacer Advisors Inc. grew its holdings in shares of Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Jazz Pharmaceuticals by 4.6% in the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after buying an additional 48,708 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.